The results showed that CD2BP2‐DT downregulation significantly inhibited xenograft tumor proliferation in vivo, while CD2BP2‐DT overexpression significantly promoted proliferation (Figure 2F–I). This evidence concerns the gene CD2BP2 and neoplasm.